Compare ABLV & PDSB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ABLV | PDSB |
|---|---|---|
| Founded | 2015 | 2005 |
| Country | China | United States |
| Employees | 89 | 10 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.1M | 37.5M |
| IPO Year | N/A | 2015 |
| Metric | ABLV | PDSB |
|---|---|---|
| Price | $0.69 | $0.64 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 5.2K | ★ 298.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 25.90 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $16.70 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.59 | $0.60 |
| 52 Week High | $1.77 | $1.90 |
| Indicator | ABLV | PDSB |
|---|---|---|
| Relative Strength Index (RSI) | 39.23 | 40.05 |
| Support Level | $0.60 | $0.62 |
| Resistance Level | $0.97 | $1.16 |
| Average True Range (ATR) | 0.03 | 0.05 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 24.24 | 18.37 |
Able View Global Inc operates as a brand management partner of international beauty and personal care brands in China. It provides full-service solutions covering marketing plan, branding, digital and social marketing, omni-channel sales, customer service, overseas logistics, warehouse, and fulfillment. The firm generates revenue from product sales by distributing and selling cross-border products from various brand owners to Chinese consumers.
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.